{"disease":{"id":"head-and-neck-squamous-cell-carcinomas","name":"head and neck squamous cell carcinomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06297811","title":"Myeloprotection With Trilaciclib in Pan-cancer Population","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05482880","title":"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04992559","title":"A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06235918","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Xiang Lu","has_results":false},{"nct_id":"NCT05724329","title":"Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05233436","title":"PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Pfizer","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}